Spinogenix, Inc.

Fragile X News Today spotlights the promising impact of #SPG601 in reducing abnormal brain activity in Fragile X syndrome, the leading inherited form of intellectual disability and a known cause of autism. This coverage underscores the growing recognition of our work in advancing a new treatment that works at the synaptic level to improve core symptoms and challenging behaviors with the hope to enhance the overall quality of life for those affected. Read the full article here | https://lnkd.in/eH7qjRyV. #FragileX #Neurology #SynapseRestoration #RegenerativeMedicine #Neurodegeneration #FXS

The search for effective treatments for #ALS continues, but progress has been challenging. The recent results from the HEALEY ALS Platform Trial underscore the difficulty of developing new therapies for this devastating condition. And current therapies available to most ALS patients offer only a very modest extension of life. Despite setbacks, innovation continues, and new approaches offer hope. Spinogenix’s SPG302 is a first-in-class synaptic regenerative drug tablet aimed at reversing declines in cognitive, motor, and respiratory function. Unlike therapies that focus on slowing degeneration, SPG302 is the first treatment designed to potentially restore function, offering new hope for people with ALS. SPG302 has received FDA orphan drug designation and is currently in phase 2 clinical trials. Learn more about our ALS mission and the importance of synapse regeneration | https://lnkd.in/gbfiaUb4. #Neuroscience #Biotech #Spinogenix #SynapseRestoration #RegenerativeMedicine #Neurodegeneration

Schizophrenia affects millions worldwide, yet existing treatments primarily focus on symptom management rather than addressing the underlying biology. Research shows that synapse loss is a key factor in cognitive deficits and functional decline. At Spinogenix, we are pioneering the first synaptic regenerative therapy for schizophrenia, with the potential to restore cognitive function, reduce symptoms and improve patient outcomes. Learn more about how synapse regeneration could transform schizophrenia treatment | https://lnkd.in/eruCU7sV. #Schizophrenia #Neuroscience #SynapseRegeneration #Spinogenix #RegenerativeMedicine

Current Alzheimer’s treatments focus on slowing progression—but what if we could go beyond that? At Spinogenix, we’ve developed the first synaptic regenerative therapy designed to restore lost cognitive function. SPG302 is a once-daily tablet that aims to rebuild synapses—the brain’s key connections for memory and cognition—offering hope?for a more accessible and effective alternative to?current treatments. Our Phase 2 clinical trials in Australia are advancing this groundbreaking approach. ? Learn more about how targeting synapses could change the future of Alzheimer’s treatment |?https://lnkd.in/g8Uhi4r5. ? #Alzheimers #Neuroscience #ClinicalTrials #SynapseRestoration #Spinogenix #RegenerativeMedicine

Last night at the NIH Fragile X Centers of Excellence Update conference, Dr. Craig Erickson, Spinogenix Chief Medical Advisor, announced promising Phase 2 study results for SPG601, a new therapy for Fragile X syndrome (FXS): a genetic disorder, the leading inherited cause of intellectual disability, and a known cause of autism. SPG601 is designed to improve core symptoms of FXS by targeting a key molecular dysfunction at the synaptic level. With no approved treatments currently available, Spinogenix is committed to advancing this much-needed therapy to enhance the overall quality of life for those affected. Dr. Erickson, who served as principal investigator of the study conducted at Cincinnati Children's, said, “This is the strongest test result to date demonstrating a therapy normalizing gamma band activity, which is directly associated with learning, memory, and typical brain activity.” The FDA granted Orphan Drug and Fast Track designation to SPG601, and Spinogenix and Cincinnati Children’s are completing analysis of the full study results in preparation for publication. Stay tuned for what’s ahead | https://lnkd.in/gWNX8P8V. #FragileX #FXS #Neuroscience #FragileXResearch #CincinnatiChildrens #FragileXCommunity #PharmaInnovation #ClinicalResearch #ClinicalTrials

We are thrilled to share that Dr. Craig Erickson, Spinogenix Chief Medical Advisor, will present our Phase 2 study results of SPG601 to treat #FXS at the NIH Fragile X Centers of Excellence Conference on February 10. With Orphan Drug and Fast Track designations granted from the FDA, SPG601 and this research, conducted at Cincinnati Children's, represent an important step forward in advancing hope for a novel new therapy for the Fragile X community. Dr. Erickson is the principal investigator of the SPG601 Phase 2 study in FXS and also the research director and an associate professor in the Division of Child and Adolescent Psychiatry at Cincinnati Children’s, where he and his lab team study translational treatment development for neurodevelopmental disorders, with a focus on FXS and autism spectrum disorder. Families, researchers, and advocates interested in learning more about this breakthrough study can register for free to attend the webinar. Sign up here |?https://lnkd.in/gvq-KDD8. #FragileX #FragileXResearch #CincinnatiChildrens #FragileXCommunity

Recent FDA approvals mark a major milestone in the fight against #AlzheimersDisease, and at Spinogenix, we’re excited about what’s ahead. While these advancements are encouraging, the next step is?regenerating the?synapses?lost in AD—which means restoring cognitive function. ? Our Founder & CEO, Dr. Stella Sarraf, PhD, spoke with PharmaShots about our groundbreaking approach,?by?targeting synapses?with the potential to reverse cognitive decline and improve patient outcomes. ? Read the full interview to learn more about our innovative approach |?https://lnkd.in/dfrtHeMR. ? #AlzheimersResearch #Neurodegeneration #Biotech #Innovation #Spinogenix?#regenerativemedicine

#FragileXsyndrome (FXS)?is a common inherited form of #autism, affecting thousands of families worldwide. Individuals with FXS face challenges like severe anxiety, sensory sensitivities, and developmental seizures, placing an immense emotional and financial burden on caregivers. In the U.S. alone, direct family healthcare costs for FXS total $4.1 billion annually. Despite this impact, there are no FDA-approved treatments for FXS—leaving this community underserved. ? At Spinogenix, we’re committed to changing that. Our work focuses on restoring synaptic health, and our innovative therapy, SPG601, recently received FDA Fast Track Designation. This milestone represents hope for families impacted by FXS and autism as we strive to address this critical unmet need. ? Learn more about our science and how we’re advancing solutions for Fragile X:?https://lnkd.in/gZM_R568. ? National Fragile X Foundation, FRAXA Research Foundation, Autism Speaks.

Spinogenix is transforming the treatment landscape for a wide range of diseases by targeting a common and fundamental feature: synapse deterioration. These neurodegenerative, neuropsychiatric, and neurodevelopmental conditions, including #Alzheimer’s, #ALS, #Schizophrenia, #FragileXSyndrome—collectively known as “synaptopathies”—share a progressive loss of synapses as a hallmark. Synapses are the vital connections between neurons that enable cognition, movement, perception, memory, and more. Their loss is not just an early marker of disease but a critical driver of its progression. At Spinogenix, we are pioneering first-in-class therapeutics designed to restore synapses, offering the potential to reverse disease?at their core. Our innovative approach is grounded?in?addressing the root cause of synaptopathies, setting a new standard for the future of neuroscience therapeutics. Learn more about us on our website |?https://lnkd.in/gbfiaUb4. ? #Spinogenix?#NeurologicalInnovation

Spinogenix is honored to be featured in NeurologyLive for our work on SPG-601, which has received FDA Fast Track Designation for Fragile X Syndrome. This coverage highlights the significance of this milestone in advancing treatment options for this challenging condition, which is a common inherited form of autism. Explore the article to learn more about the potential of SPG-601 and what this designation means for patients |?https://lnkd.in/eKqRm7sm. ? #NeurologyLive #Spinogenix #FragileXSyndrome #FDAFastTrack #NeurologicalInnovation